News

HCC is the most common form of liver cancer, a disease that affects nearly 40,000 patients in the United States and is the second deadliest form of cancer

APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic

Duzallo, which is a fixed-dose combination of lesinurad and allopurinol, is intended to treat hyperuricemia in patients with uncontrolled gout. The drug is likely to be commercially launched in

In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGR achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c)

In addition, Shire’s former MRT employees, the group focused on the development of this technology since 2008, have joined RaNA to continue to advance the platform with lead

The randomized, double-blind, vehicle controlled phase 3 confirmatory study included 744 patients. The primary endpoint of statistically significant improvement in Schirmer's score (a measurement of tear production) was

The clinical trial is evaluating the efficacy and safety of Quisinostat in platinum-resistant ovarian cancer in combination with Paclitaxel and Carboplatin. The detailed results will be presented in

Cannabics Pharmaceuticals chief scientist Eyal Ballan stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on

Charles Theuer, M.D., Ph.D., President and CEO of TRACON, said: “The SPA agreement represents a significant milestone for TRACON, as it provides us with a clearly defined development